David Iosseliani

David Iosseliani

Auto-generated profile, based on publicly available information

David Iosseliani

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
MBMarina G. Bubnova
Marina G. Bubnova
ESE. V. Shlyakhto
E. V. Shlyakhto
DAD. M. Aronov
D. M. Aronov
ABA. S. Belevsky
A. S. Belevsky
MGM. Yu. Gerasimenko
M. Yu. Gerasimenko
VTV. A. Tutelian
V. A. Tutelian
The expert consensus of the Russian communities discusses the issues of comprehensive medical rehabilitation of patients with coronavirus disease 2019 (COVID-19). COVID-19 is a contagious infectious disease that can cause pulmonary, cardiac, motor, metabolic, neurocognitive and mental disorders, that is, multiple organ dysfunction. COVID-19 survivors, especially after a severe clinical course, face serious psychological and physical problems, posttraumatic stress, cognitive dysfunction, nutritional deficiencies and exacerbation of concomitant chronic diseases. Some patients, regardless of the COVID-19 severity, have a long clinical course of the disease (“chronic-COVID”, “long COVID”). There is evidence of post-acute COVID-19 syndrome. In this regard, patients after COVID-19 will need rehabilitation measures. The expert consensus of the Russian communities presents general principles, stages and aspects of medical rehabilitation after COVID-19, indications and contraindications for rehabilitation interventions. The paper includes recommendations on comprehensive cardiac and pulmonary rehabilitation, as well as specifics of rehabilitation care for different COVID-19 courses within the national three-stage rehabilitation system.

28 February 2021 in Kardiologiia
Verified
Journal Article
Open access
PDF file
AZA. S. Zhuravlev
A. S. Zhuravlev
AAA. V. Azarov
A. V. Azarov
SSS. P. Semitko
S. P. Semitko
DID. G. Ioseliani
D. G. Ioseliani
Despite successful and timely revascularization of the infarct-related artery, myocardial tissue remains underperfused in some patients. This condition is known as the no-reflow phenomenon, which is associated with a worse prognosis. The first part of the systematic review on no-reflow focuses on description of the no-reflow pathogenesis and predictors. This phenomenon has a complicated, multifactorial pathogenesis, including distal embolization, ischemic injury, reperfusion injury, and a component of individual predisposition. Meanwhile, this phenomenon undergoes spontaneous regression in some patients. Several studies have demonstrated the role of definite biomarkers and clinical indexes as risk predictors for no-reflow. The significance of each pathogenetic component of no-reflow is suggested to be different in different patients, which may warrant an individualized approach in the treatment.

4 July 2021 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
AAA. V. Azarov
A. V. Azarov
SSS. P. Semitko
S. P. Semitko
AZA. S. Zhuravlev
A. S. Zhuravlev
DID. G. Ioseliani
D. G. Ioseliani
IKI. Kh. Kamolov
I. Kh. Kamolov
IKI. A. Kovalchuk
I. A. Kovalchuk
Aim. To assess whether delayed coronary artery stenting (CAS) can reduce the slow/no-reflow incidence in patients with ST-segment elevation myocardial infarction (STEMI) and massive thrombosis (TTG ≥3) of the infarct-related coronary artery (IRCA) compared with immediate CAS within primary PCI.Material and methods. Out of 3651 primary PCIs performed for acute STEMI in the period from January 2016 to May 2020 at the Mytishchi City Clinical Hospital, the retrospective analysis included 105 patients with massive IRCA thrombosis (TTG ≥3). The patients were divided into two groups: first group (n=55) — delayed CAS, second group (n=50) — immediate CAS. In the immediate CAS group, the PCI procedure ended with routine stent implantation, and in the delayed CAS group, stent implantation was delayed for at least 5 days.Results. In the delayed CAS group in comparison with immediate one, the slow/no-reflow phenomenon developed much less frequently in the form of a significant increase in the prevalence of TIMI 3 flow, better myocardial perfusion of myocardial blush grade (MBG) 2-3 (81,8 vs 64%; odds ratio (OR) 2,53; p=0,039) and ST segment resolution ≥70% (87,3% vs 58%; OR 4,97; p=0,001).Conclusion. Delayed CAS in patients with STEMI with massive thrombosis (TTG ≥3) of IRCA reduces the risk of slow/no-reflow phenomenon and can be considered as a possible alternative treatment vs immediate CAS, provided that stable coronary flow is restored before TIMI 3.


30 November 2022 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
IRI. R. Rafaeli
I. R. Rafaeli
AKA. Iu. Kireeva
A. Iu. Kireeva
NTN. V. Tsereteli
N. V. Tsereteli
ARA. N. Rogatova
A. N. Rogatova
SSS. P. Semitko
S. P. Semitko
DID. G. Ioseliani
D. G. Ioseliani
Aim      To study the effect of the baseline severity of coronary artery damage according to the SYNTAX scale (baseline score of coronary lesions, BSCL) on the mid-term prognosis in patients with non-ST segment elevation acute myocardial infarction (AMI) (NSTEMI), and to identify the threshold BSCL value that determines high and low risks of adverse cardiac outcomes. Material and methods  A retrospective analysis was performed for the hospital treatment of patients with NSTEMI (n=421) who had undergone percutaneous coronary intervention (PCI). 256 patients with a repeated hospitalization in mid-term (11.6±3.2 months) were selected for the study. These patients were followed up for the incidence of acute coronary syndrome (ACS), unscheduled repeated myocardial revascularization (URR), and of the composite endpoint (CEP) that included at least one the following events: death, recurrent AMI, unstable angina (UA), and URR. The effect of BSCL on the incidence of these events in mid-term was proven (р<0.05), and then the BSCL threshold value was determined, which allowed segregation of patients into groups of high and low risk of adverse cardiac outcomes. Results The threshold BSCL value for the risk of ACS was determined as score 14 (odds ratio, OR, 2.79; 95 % confidence interval, CI: 1.32–5.89); for URR and CEP, score 13 (OR, 2.21; 95 % CI: 1.22–4.01 and OR, 2.38; 95 % CI: 1.32–4.31, respectively). Since these threshold values were comparable, for the composite category of events (CEP), the BSCL threshold comprised score 13, and namely this value was taken as a base. According to the multifactorial Cox regression at BSCL score ≥13, the probability of earlier CEP in mid-term was 2.44 times higher than at lower BSCL values (OR, 2.44; 95 % CI: 1.41–4.21; р=0.001). Furthermore, according to the Kaplan-Meier estimate, the effect of BSCL on the survival without adverse cardiac outcomes becomes significant starting from the second half-year (р=0.001, log-rank test). Conclusion      In NSTEMI patients, the SYNTAX baseline score of coronary lesions > 13 is an independent predictor of adverse cardiac outcomes in mid-term starting from the second half-year. Thus, patients with BSCL ≥13 should undergo a follow-up examination no later than at 6 months independent on their clinical condition. .

22 July 2022 in Almanac of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AAAlexey V. Azarov
Alexey V. Azarov
MGMaria G. Glezer
Maria G. Glezer
AZAndrey S. Zhuravlev
Andrey S. Zhuravlev
ABAvtandil M. Babunashvili
Avtandil M. Babunashvili
SSSergey P. Semitko
Sergey P. Semitko
DIDavid G. Ioseliani
David G. Ioseliani
Background: There have been a big number of studies assessing the efficacy of delayed coronary artery stenting (DCAS) in the prevention of no-reflow microvasculature injury compared to the standard immediate coronary artery stenting (ICAS) in ST-segment elevation myocardial infarction (STEMI). However, the results of these studies are contradictory in a lot of ways. Aim: To summarize studies on the assessment of DCAS in the prevention of no-reflow compared to the standard ICAS. Materials and methods: We performed a systematic literature search in PubMed, Google Scholar, and eLIBRARY.RU databases. The analysis included 17 studies with a total sample of 3505 patients. The comparative analysis included angiography-based endpoints prevalence of no-reflow (thrombolysis in myocardial infarction, TIMI 3 and myocardial blush grade, MBG 2, corrected TIMI frame count, CTFC) and clinical endpoints of all-cause mortality, cardiovascular mortality, major adverse cardiac events (MACE), recurrent myocardial infarction and recurrent revascularization. In addition, the analysis included the assessment of ST-elevation resolution, left ventricular ejection fraction values in the delayed post-intervention period and between-group differences. Results: The no-reflow phenomenon was significantly less frequent in the DCAS groups for the following parameters: epicardial flow TIMI 3 (odds ratio (OR) 2.00; 95% confidence interval (CI) 1.492.69; p 0.00001; I = 16%), myocardial perfusion MBG 2 (OR 4.69; 95% CI 1.9811.14; p = 0.0005; I = 59%), CTFC (mean difference (MD) 10.29; 95% CI 0.9619.62; p = 0.03; I = 96%). The analysis of secondary endpoints showed that MACE were less frequent in the DCAS groups (OR 1.29; 95% CI 1.041.60; p = 0.02; I = 42%), the difference becoming more significant in the studies with high initial thrombotic burden (TTG 3) (OR 1.83; 95% CI 1.282.62; p = 0.0009; I = 41%). The most clinically significant decrease of the MACE rate was found in 5 studies (n = 656) with high initial thrombotic burden (TTG 3) and mean time to repeated intervention from 4 to 7 days (OR 3.15; 95% CI 1.865.32; p 0.0001; I = 0%). The reverse trend for a benefit in the ICAS group was observed in the studies with a high initial thrombotic burden (TTG 3) and mean time to recurrent intervention of 48 hours (OR 0.60; 95% CI 0.301.19; p = 0.14; I = 20%). The ICAS and DCAS groups did not differ in overall mortality (p = 0.31), cardiovascular mortality (p = 0.49), repeated revascularization (p = 0.66), and ST resolution of 70% (p = 0.65). In the DCAS groups, there was an obvious trend to lower incidence of recurrent myocardial infarction (OR 1.28; 95% CI 0.951.73; p = 0.10; I = 0%), as well as to higher myocardial mass during the deferred analysis of left ventricular ejection fraction (OR -0.79; 95% CI -1.61 -0.04; p = 0.06; I = 36%). Conclusion: Deferred coronary artery stenting is an effective method for prevention of no-reflow. In patients with extended coronary thrombosis (TTG 3) and STEMI, the DCAS technique with time to recurrent intervention of 4 to 7 days decreases the probability of MACE compared to that with immediate stenting of the index coronary artery.